Genmab's Epcoritamab Gets FDA Orphan-Drug Designation in Follicular Lymphoma

• (PLX AI) - Genmab Announces U.S. Food and Drug Administration Granted Orphan-Drug Designation to Epcoritamab (DuoBody-CD3xCD20) in Follicular Lymphoma.
• • Epcoritamab is being co-developed by Genmab and AbbVie
• • Orphan drug status is designated by the FDA to medicines and biologics that are defined as those intended for the prevention, diagnosis, or treatment of a rare disease or condition affecting less than 200,000 people in the U.S.